Anticholinergic Medication and Caries Status Predict Xerostomia under 65

The use of anticholinergic medications is increasing in younger ages, yet information about xerostomia, the most common anticholinergic side effect, is limited. This case–control retrospective study examines the relationship between anticholinergic medication-induced xerostomia and caries status among adults between 18 and 65 years of age. The study sample comprised 649 cases with xerostomia and 649 age- and gender-matched controls. The anticholinergic burden was estimated using the anticholinergic drug scale (ADS). Caries experience was recorded by calculating the Decayed, Missing, Filled Tooth (DMFT) index. Individuals with xerostomia had a higher mean DMFT index (16.02 ± 9.50), which corresponded with a higher level of anticholinergic exposure from medications (3.26 ± 2.81) compared to their age and gender-matched controls without xerostomia (13.83 + 8.83 and 1.89 ± 2.45, respectively). Logistic regression analysis verified the effects of DMFT, the total number of AC medications, and the ADS burden on xerostomia status. Comparing adults with or without xerostomia revealed statistical differences in several risk factors, such as smoking, diabetes, sleep apnea, and the utilization of anticholinergic medications. A personalized dental care plan should include the evaluation of the anticholinergic burden from medications regardless of the patient’s age to prevent increased caries severity.

[1]  A. Vissink,et al.  Impact of medications on salivary flow rate in patients with xerostomia: a retrospective study by the Xeromeds Consortium , 2022, Clinical Oral Investigations.

[2]  Kazuki Ikai,et al.  Analysis of medication-induced xerostomia in elderly Japanese patients , 2021, Clinical oral investigations.

[3]  D. Kopycka-Kedzierawski,et al.  Anticholinergic medication-related dry mouth and effects on the salivary glands. , 2021, Oral surgery, oral medicine, oral pathology and oral radiology.

[4]  V. Anttonen,et al.  Anticholinergic burden, oral hygiene practices, and oral hygiene status—cross-sectional findings from the Northern Finland Birth Cohort 1966 , 2020, Clinical Oral Investigations.

[5]  K. Dewan,et al.  Where Dysphagia Begins: Polypharmacy and Xerostomia. , 2020, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[6]  Gilles Amador,et al.  Anticholinergic Drugs and Oral Health-related Quality of Life in Patients with Schizophrenia: A Pilot Study , 2020, Translational neuroscience.

[7]  A. Kullaa,et al.  Anticholinergic Burden and Dry Mouth in Middle-Aged People , 2019, JDR clinical and translational research.

[8]  D. Carroll,et al.  Polypharmacy: Evaluating Risks and Deprescribing. , 2019, American family physician.

[9]  E. Menditto,et al.  Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis , 2019, PloS one.

[10]  P. Lichtenstein,et al.  Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: a population-based study in Sweden , 2019, European Child & Adolescent Psychiatry.

[11]  K. Johnell,et al.  The Effect of Xerostomic Medication on Oral Health in Persons With Dementia. , 2018, Journal of the American Medical Directors Association.

[12]  W. M. Thomson,et al.  How Common is Dry Mouth? Systematic Review and Meta-Regression Analysis of Prevalence Estimates. , 2018, Brazilian dental journal.

[13]  M. Zins,et al.  Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  M. Petrovic,et al.  The impact of a preventive and curative oral healthcare program on the prevalence and incidence of oral health problems in nursing home residents , 2018, PloS one.

[15]  C. Rustichelli,et al.  Polypharmacy Among Headache Patients: A Cross-Sectional Study , 2018, CNS Drugs.

[16]  S. Hartikainen,et al.  Anticholinergic burden and dry mouth among Finnish, community‐dwelling older adults , 2018, Gerodontology.

[17]  D. Jager,et al.  Clinical oral dryness score: evaluation of a new screening method for oral dryness , 2018, Odontology.

[18]  K. Johnell,et al.  Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Metaanalysis , 2018, Journal of the American Geriatrics Society.

[19]  K. Peres,et al.  General health influences episodes of xerostomia: a prospective population‐based study , 2017, Community dentistry and oral epidemiology.

[20]  F. Nordio,et al.  A risk prediction model for xerostomia: a retrospective cohort study. , 2016, Gerodontology.

[21]  Yi-Hsin Yang,et al.  Antipsychotic medications and dental caries in newly diagnosed schizophrenia: A nationwide cohort study , 2016, Psychiatry Research.

[22]  Mengmeng Du,et al.  Trends in Dietary Supplement Use Among US Adults From 1999-2012. , 2016, JAMA.

[23]  Y. Fujiwara,et al.  Prevalence and factors associated with xerostomia and hyposalivation among community-dwelling older people in Japan. , 2016, Gerodontology.

[24]  A. Vissink,et al.  World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[25]  Michael L. Johnson,et al.  Potentially Inappropriate Anticholinergic Medication Use in Community-Dwelling Older Adults: A National Cross-Sectional Study , 2015, Drugs & Aging.

[26]  W. Thomson.  Dry mouth and older people. , 2015, Australian dental journal.

[27]  E. Molden,et al.  Association Between Inherited CYP2D6/2C19 Phenotypes and Anticholinergic Measures in Elderly Patients Using Anticholinergic Drugs , 2013, Therapeutic drug monitoring.

[28]  R. V. Vander Stichele,et al.  Systematic review of anticholinergic risk scales in older adults , 2013, European Journal of Clinical Pharmacology.

[29]  K. Engedal,et al.  Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. , 2013, British journal of clinical pharmacology.

[30]  M. Rad,et al.  Effect of Long-term Smoking on Whole-mouth Salivary Flow Rate and Oral Health , 2010, Journal of dental research, dental clinics, dental prospects.

[31]  I. Kaplan,et al.  Major salivary gland output differs between users and non-users of specific medication categories. , 2008, Gerodontology.

[32]  B. Pollock,et al.  The Anticholinergic Drug Scale as a Measure of Drug‐Related Anticholinergic Burden: Associations With Serum Anticholinergic Activity , 2006, Journal of clinical pharmacology.

[33]  R. Poulton,et al.  The impact of xerostomia on oral-health-related quality of life among younger adults , 2006, Health and quality of life outcomes.

[34]  C. Scully,et al.  Drug effects on salivary glands: dry mouth. , 2003, Oral diseases.

[35]  D. Norman,et al.  Late-life depression: psychopathology, medical interventions, and dental implications. , 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[36]  S. Higham,et al.  Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice. , 2001, Gerodontology.

[37]  A. Bardow,et al.  Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. , 2001, Archives of oral biology.

[38]  C. Dahlöf,et al.  Prevalence of perceived symptoms of dry mouth in an adult Swedish population--relation to age, sex and pharmacotherapy. , 1997, Community dentistry and oral epidemiology.

[39]  L. Tune,et al.  ASSOCIATION OF POSTOPERATIVE DELIRIUM WITH RAISED SERUM LEVELS OF ANTICHOLINERGIC DRUGS , 1981, The Lancet.

[40]  P. Pannu,et al.  Correlation of oral hygiene practices, smoking and oral health conditions with self perceived halitosis amongst undergraduate dental students , 2014, Journal of natural science, biology, and medicine.

[41]  A. Bardow,et al.  The buffer capacity and buffer systems of human whole saliva measured without loss of CO2. , 2000, Archives of oral biology.

[42]  G. Tollefson,et al.  The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[43]  S. Litton,et al.  Oral manifestations of Sjogren's syndrome. , 1988, Northwest dentistry.